Bayer Partners with NextRNA Therapeutics to Develop Small Molecules Targeting Long Non-Coding RNAs (lncRNAs) for Oncology
Shots:
- Bayer & NextRNA Therapeutics will jointly develop 2 oncology programs, with one under non-clinical evaluation at NextRNA and another targeting lncRNAs identified by NextRNA’s platform. Bayer has the option to select one of these targets for joint development
- The partnership provides Bayer with access to NextRNA’s approach that inhibits lncRNAs function with small molecule. NextRNA’s platform integrates computational engine NextMap with lncRNA biology expertise and a set of biochemical, biophysics & chemistry capabilities
- NextRNA is eligible to get up to $547M as upfront, near-term development & commercial milestones, research funding as well as royalties on net sales for the two programs
Ref: Bayer | Image: Bayer & NextRNA Therapeutics
Related Post: Bayer Reports the P-III (FINEARTS-HF) Study Data of Finerenone to Prevent Heart Failure with Preserved Ejection Fraction
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
